First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors
NCT04675996
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
25
Enrollment
INDUSTRY
Sponsor class
Stopped
insufficient funding
Conditions
Solid Tumor
Interventions
DRUG:
INT-1B3
Sponsor
InteRNA